Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys.
ezetimibe
hepatitis C
kidney transplantation
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
24
08
2021
received:
26
05
2021
accepted:
10
09
2021
pubmed:
16
9
2021
medline:
3
2
2022
entrez:
15
9
2021
Statut:
ppublish
Résumé
Kidney transplantation (KT) from hepatitis C virus infected (HCV+) donors to HCV negative recipients achieve excellent graft function but have relatively higher rates of post-KT co-infections presumably due to prolonged HCV viremia in transmission-and-treat approach. Ezetimibe acts as an antagonist of Niemann-Pick C1-Like 1 receptor required for HCV entry and theoretically can reduce HCV viremia. However, no data is available to examine the role of ezetimibe as a bridge therapy between KT surgery and direct acting antiviral (DAA) initiation. A retrospective cohort study including 70 HCV+ to HCV negative KT recipients from Methodist University Hospital and Vanderbilt University Medical Center was performed to determine the association between ezetimibe usage and HCV viremia. Twenty patients received ezetimibe daily while 50 patients did not. Primary outcome of study was mean HCV RNA level at 1-2 weeks post-KT and before initiation of DAA. Median (IQR) viral load (VL) in log copies/ml was one log lower in ezetimibe group versus non-ezetimibe group (4.1 [3.7-5.3] vs. 5.1 [4.4-5.5], P = .01), and highest VL was also lower in ezetimibe group (4.2 [3.7-5.4] vs. 5.4 [4.7-5.9], P = .006). We concluded that ezetimibe bridge therapy might be associated with reduction in HCV VL while waiting for DAA initiation in HCV+ to HCV negative KT recipients.
Substances chimiques
Antiviral Agents
0
RNA
63231-63-0
Ezetimibe
EOR26LQQ24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14485Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Potluri VS, Goldberg DS, Mohan S, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol. 2019;30(10):1939-1951.
Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019;19(11):3046-3057.
Pauli D, White JW, Andrade-Sanchez P, et al. Investigation of the influence of leaf thickness on canopy reflectance and physiological traits in upland and pima cotton populations. Front Plant Sci. 2017;8:1405.
Gupta G, Zhang Y, Carroll NV, Sterling RK. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant. 2018;18(10):2496-2505.
Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395.
Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis c virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540.
Gupta G, Yakubu I, Bhati CS, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant. 2020;20(3):739-751.
Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of kidneys from hepatitis c virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis. 2021;77(5):739-747.
Khan ST, Karges W, Cooper CL, Crawley AM. Hepatitis C virus core protein reduces CD8(+) T-cell proliferation, perforin production and degranulation but increases STAT5 activation. Immunology. 2018;154(1):156-165.
Christiaansen A, Varga SM, Spencer JV. Viral manipulation of the host immune response. Curr Opin Immunol. 2015;36:54-60.
Bhattarai N, McLinden JH, Xiang J, et al. Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathog. 2017;13(2):e1006232.
Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: a unique complication in the DAA era. Am J Transplant. 2020;20(2):600-605.
Del Campo JA, Rojas A, Romero-Gomez M. Entry of hepatitis C virus into the cell: a therapeutic target. World J Gastroenterol. 2012;18(33):4481-4485.
Monrroy-Bravo H, Angulo J, Pino K, Labbe P, Lopez-Lastra M, Soza A. Effect of ezetimibe in HCV viral load after liver transplantation. Ann Hepatol. 2016;15(5):803-805.
Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012;18(2):281-285.
Soza A. Hepatitis C RNA clearance after treatment with ezetimibe. Liver Int. 2012;32(8):1323-1324.
Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5(7):649-657.
Romero-Marrero C, Combination therapy prevents HCV infection in non-viremic organ recipients. Helio.com2020. p. https://www.healio.com/news/hepatology/20191110/combination-therapy-prevents-hcv-infection-in-nonviremic-organ-recipients
Lentine KL, Peipert JD, Alhamad T, et al. Survey of clinician opinions on kidney transplantation from hepatitis c virus positive donors: identifying and overcoming barriers. Kidney360. 2020;1(11):1291-1299.
Roth D, Bloom RD, Molnar MZ, et al. KDOQI US commentary on the 2018 KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C. Am J Kidney Dis. 2020;75(5):665-683.